QIAGEN (NYSE:QGEN) Rating Lowered to Hold at Wall Street Zen

QIAGEN (NYSE:QGEN) was downgraded by equities research analysts at Wall Street Zen from a “buy” rating to a “hold” rating in a research note issued to investors on Saturday.

A number of other equities research analysts also recently weighed in on the company. Bank of America boosted their price target on QIAGEN from $50.00 to $53.00 and gave the company a “buy” rating in a report on Thursday, June 26th. Barclays set a $53.00 price target on QIAGEN and gave the company an “overweight” rating in a report on Thursday, October 2nd. UBS Group boosted their price target on QIAGEN from $48.00 to $50.00 and gave the company a “neutral” rating in a report on Thursday, August 7th. Weiss Ratings reiterated a “hold (c+)” rating on shares of QIAGEN in a report on Wednesday, October 8th. Finally, Cowen reiterated a “hold” rating on shares of QIAGEN in a report on Thursday, August 7th. Three equities research analysts have rated the stock with a Buy rating and nine have assigned a Hold rating to the company’s stock. According to data from MarketBeat.com, the company has a consensus rating of “Hold” and an average price target of $49.40.

QIAGEN Price Performance

QGEN stock opened at $46.93 on Friday. The company has a quick ratio of 1.35, a current ratio of 1.61 and a debt-to-equity ratio of 0.25. QIAGEN has a 52-week low of $37.63 and a 52-week high of $51.88. The stock’s 50 day moving average is $47.11 and its two-hundred day moving average is $45.58. The company has a market capitalization of $10.43 billion, a PE ratio of 27.73, a P/E/G ratio of 2.46 and a beta of 0.66.

QIAGEN (NYSE:QGEN) last issued its quarterly earnings results on Tuesday, August 5th. The company reported $0.60 earnings per share for the quarter, meeting analysts’ consensus estimates of $0.60. QIAGEN had a return on equity of 14.77% and a net margin of 18.30%.The business had revenue of $533.54 million during the quarter, compared to the consensus estimate of $523.97 million. During the same period in the previous year, the business earned $0.55 EPS. The business’s quarterly revenue was up 7.7% on a year-over-year basis. QIAGEN has set its Q3 2025 guidance at 0.580- EPS. FY 2025 guidance at 2.350-2.350 EPS. Analysts predict that QIAGEN will post 2.26 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

A number of institutional investors have recently added to or reduced their stakes in QGEN. Price T Rowe Associates Inc. MD grew its stake in QIAGEN by 3,030.9% during the 1st quarter. Price T Rowe Associates Inc. MD now owns 4,470,728 shares of the company’s stock worth $179,501,000 after buying an additional 4,327,934 shares during the last quarter. Norges Bank acquired a new position in QIAGEN during the 2nd quarter worth $158,728,000. Wellington Management Group LLP boosted its position in QIAGEN by 12.2% during the 1st quarter. Wellington Management Group LLP now owns 24,438,441 shares of the company’s stock worth $972,191,000 after acquiring an additional 2,656,136 shares during the period. Deutsche Bank AG boosted its position in QIAGEN by 57.5% during the 1st quarter. Deutsche Bank AG now owns 4,491,131 shares of the company’s stock worth $180,319,000 after acquiring an additional 1,639,621 shares during the period. Finally, Nuveen LLC acquired a new position in QIAGEN during the 1st quarter worth $44,078,000. 70.00% of the stock is currently owned by institutional investors.

QIAGEN Company Profile

QIAGEN NV is a holding company, which engages in the provision of Sample to Insight solutions that enable customers to gain valuable molecular insights from samples containing the building blocks of life. The company sample technologies isolate and process DNA, RNA, and proteins from blood, tissue, and other materials.